Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 20/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29583917 | 0.95 | ADORA2A (0.70) | ADORA2A | |
| SCHEMBL21330958 | 0.95 | ADORA2A (0.70) | ADORA2A | |
| SCHEMBL24446021 | 0.90 | ADORA2A (0.75) | ADORA2A | |
| SCHEMBL21832528 | 0.90 | ADORA2A (0.58) | ADORA2A | |
| SCHEMBL21331011 | 0.89 | ADORA2A (0.66) | ADORA2A | |
| SCHEMBL29584733 | 0.89 | ADORA2A (0.66) | ADORA2A | |
| SCHEMBL20521426 | 0.89 | ADORA2A (0.62) | ADORA2A | |
| Hydrochloric Acid SCHEMBL21331012 | 0.89 | ADORA2A (0.66) | ADORA2A | |
| SCHEMBL21887098 | 0.88 | ADORA2A (0.75) | ADORA2A | |
| SCHEMBL24445775 | 0.88 | ADORA2A (0.77) | ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230165863-A1 | METHODS AND FORMULATIONS FOR ADMINISTRATION OF THIOCARBAMATE DERIVIATIVES A2A INHIBITORS | iTeos Belgium SA (BE) | 2023-06-01 | — | — | US | claimed |
| US-20230159564-A1 | 2-Oxo-Thiazole Derivatives as A2A Inhibitors and Compounds for Use in the Treatment of Cancers | iTeos Belgium SA (BE) | 2023-05-25 | — | — | US | claimed |
| EP-4135703-A1 | METHODS AND FORMULATIONS FOR ADMINISTRATION OF THIOCARBAMATE DERIVATIVES A2A INHIBITORS | iTeos Belgium SA (BE) | 2023-02-22 | — | — | EP | claimed |
| EP-4112623-A1 | 2-OXO-THIAZOLE DERIVATIVES AS A2A INHIBITORS AND COMPOUNDS FOR USE IN THE TREATMENT OF CANCERS | iTeos Belgium SA (BE) | 2023-01-04 | — | — | EP | claimed |
| EP-3601296-B1 | 2-OXO-THIAZOLE DERIVATIVES AS A2A INHIBITORS AND COMPOUNDS FOR USE IN THE TREATMENT OF CANCERS | iTeos Belgium SA (BE) | 2022-05-25 | — | — | EP | claimed |
| WO-2021209633-A1 | METHODS AND FORMULATIONS FOR ADMINISTRATION OF THIOCARBAMATE DERIVATIVES A2A INHIBITORS | iTeos Belgium SA (BE) | 2021-10-21 | — | — | WO | claimed |
| US-20210198281-A1 | 2-OXO-THIAZOLE DERIVATIVES AS A2A INHIBITORS AND COMPOUNDS FOR USE IN THE TREATMENT OF CANCERS | iTeos Belgium SA (BE) | 2021-07-01 | — | — | US | claimed |
| US-10995101-B2 | 2-oxo-thiazole derivatives as A2A inhibitors and compounds for use in the treatment of cancers | ITEOS THERAPEUTICS SA (BE) | 2021-05-04 | — | — | US | claimed |
| EP-3601296-A1 | 2-OXO-THIAZOLE DERIVATIVES AS A2A INHIBITORS AND COMPOUNDS FOR USE IN THE TREATMENT OF CANCERS | Iteos Therapeutics (BE) | 2020-02-05 | — | — | EP | claimed |
| US-20190276473-A1 | 2-Oxo-Thiazole Derivatives as A2A Inhibitors and Compounds for Use in the Treatment of Cancers | iTeos Belgium SA (BE) | 2019-09-12 | — | — | US | claimed |
| WO-2018178338-A1 | 2-OXO-THIAZOLE DERIVATIVES AS A2A INHIBITORS AND COMPOUNDS FOR USE IN THE TREATMENT OF CANCERS | ITEOS THERAPEUTICS (BE) | 2018-10-04 | — | — | WO | claimed |
| EP-4683923-A1 | HYDROGEN SULFATE COMPLEXES, INCLUDING SALTS, CRYSTALLINE FORMS, AND HYDRATES AND SOLVATES OF ENT1 INHIBITORS | iTeos Belgium SA (BE) | 2026-01-28 | — | — | EP | disclosed |
| WO-2025104613-A1 | ENT1 INHIBITORS IN COMBINATION WITH CHECKPOINT INHIBITORS | iTeos Belgium SA (BE) | 2025-05-22 | — | — | WO | disclosed |
| US-20240368183-A1 | Macrocyclic Compounds Having ENT1 Inhibiting Activity | iTeos Belgium SA (BE) | 2024-11-07 | — | — | US | disclosed |
| US-20240327415-A1 | Multicomponent Complexes, Including Salts, Crystalline Forms, and Hydrates and Solvates of ENT1 Inhibitors | iTeos Belgium SA (BE) | 2024-10-03 | — | — | US | disclosed |
| US-20210069196-A1 | THIOCARBAMATE DERIVATIVES AS A2A INHIBITORS, PHARMACEUTICAL COMPOSITION THEREOF AND COMBINATIONS WITH ANTICANCER AGENTS | iTeos Belgium SA (BE) | 2021-03-11 | — | — | US | disclosed |
| US-20210069196-A1 | THIOCARBAMATE DERIVATIVES AS A2A INHIBITORS, PHARMACEUTICAL COMPOSITION THEREOF AND COMBINATIONS WITH ANTICANCER AGENTS | iTeos Belgium SA (BE) | 2021-03-11 | — | — | US | disclosed |
| WO-2020053263-A1 | THIOCARBAMATE DERIVATIVES AS A2A INHIBITORS, PHARMACEUTICAL COMPOSITION THEREOF AND COMBINATIONS WITH ANTICANCER AGENTS | ITEOS THERAPEUTICS S.A. (BE) | 2020-03-19 | — | — | WO | disclosed |
| US-20190276473-A1 | 2-Oxo-Thiazole Derivatives as A2A Inhibitors and Compounds for Use in the Treatment of Cancers | iTeos Belgium SA (BE) | 2019-09-12 | — | — | US | disclosed |
| US-20190276473-A1 | 2-Oxo-Thiazole Derivatives as A2A Inhibitors and Compounds for Use in the Treatment of Cancers | iTeos Belgium SA (BE) | 2019-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10995101-B2 | 2-oxo-thiazole derivatives as A2A inhibitors and compounds for use in the treatment of cancers | ADORA2A, ADORA2B, ADORA3 | ADORA2A 1/4885 |
| US-20240368183-A1 | Macrocyclic Compounds Having ENT1 Inhibiting Activity | ENTPD5, ENTPD1, ENTPD8 | ADORA2A 1396/4885 |
| US-20190276473-A1 | 2-Oxo-Thiazole Derivatives as A2A Inhibitors and Compounds for Use in the Treatment of Cancers | ADORA2A, ADORA2B, ADORA3 | ADORA2A 1/4885 |
| US-20230165863-A1 | METHODS AND FORMULATIONS FOR ADMINISTRATION OF THIOCARBAMATE DERIVIATIVES A2A INHIBITORS | ADORA2A, ADORA2B, ADORA1 | ADORA2A 1/4885 |
| US-20230159564-A1 | 2-Oxo-Thiazole Derivatives as A2A Inhibitors and Compounds for Use in the Treatment of Cancers | ADORA2A, ADORA2B, ADORA3 | ADORA2A 1/4885 |
| US-20210198281-A1 | 2-OXO-THIAZOLE DERIVATIVES AS A2A INHIBITORS AND COMPOUNDS FOR USE IN THE TREATMENT OF CANCERS | ADORA2A, ADORA2B, ADORA3 | ADORA2A 1/4885 |
| US-20210069196-A1 | THIOCARBAMATE DERIVATIVES AS A2A INHIBITORS, PHARMACEUTICAL COMPOSITION THEREOF AND COMBINATIONS WITH ANTICANCER AGENTS | ADORA2A, ADORA2B, ADORA1 | ADORA2A 1/4885 |
| US-20240327415-A1 | Multicomponent Complexes, Including Salts, Crystalline Forms, and Hydrates and Solvates of ENT1 Inhibitors | RCC1, SLC9A1, SLC5A1 | ADORA2A 1270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.